GSK Reaffirms Its 2024 Outlook, Sees Turnover Growth Of 7%-9%, With Core Operating Profit Growth Of 11%-13%, And Core EPS Growth Of 10%-12%
Portfolio Pulse from Benzinga Newsdesk
GSK reaffirms its 2024 financial outlook, expecting turnover growth of 7%-9%, core operating profit growth of 11%-13%, and core EPS growth of 10%-12%. The company revises expectations for its segments, with vaccines expected to decrease slightly, specialty medicines to increase significantly, and general medicines to grow moderately.
October 30, 2024 | 8:39 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GSK reaffirms its 2024 financial outlook with expected turnover growth of 7%-9%, core operating profit growth of 11%-13%, and core EPS growth of 10%-12%. The company anticipates a slight decrease in vaccine turnover, significant growth in specialty medicines, and moderate growth in general medicines.
GSK's reaffirmation of its 2024 outlook with positive growth expectations in turnover, core operating profit, and EPS is likely to boost investor confidence. The significant growth in specialty medicines and moderate growth in general medicines are positive indicators, despite a slight decrease in vaccine turnover.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100